The FDA has rejected Japanese drugmaker Eisai’s patch version of its Alzheimer’s disease drug Aricept (donepezil transdermal system), according to Pharma Times.

Eisai revealed that U.S. regulators have issued a complete response letter to its partner Teikoku Pharma, who developed the patch, regarding the New Drug Application.  Teikoku Pharma is seeking approval for the patch, used weekly, as a treatment of mild, moderate and severe stages of Alzheimer’s.